AMENDMENT No. 2 to Clinical Study Agreement for the study entitled “Clinical Research in Patients affected by Parkinson’s Disease Using Direct Delivery of the GAD Genes in the Brain”, under the direction of Dr. Michael G. Kaplitt, Principal InvestigatorClinical Study Agreement • March 7th, 2007 • Neurologix Inc/De • Pharmaceutical preparations
Contract Type FiledMarch 7th, 2007 Company IndustryTHIS AMENDMENT TO THE CLINICAL STUDY AGREEMENT (“Amendment No. 2”) is by and between Cornell University for its Medical College (“the Medical College”) and Neurologix, Inc. (“Sponsor”).